Broadcasting

Milestone Scientific Schedules Second Quarter 2023 Financial Results and Business Update Conference Call

Retrieved on: 
Wednesday, August 9, 2023
Telephone, Injection, Webcast, NYSE, MLSS, Broadcasting

ROSELAND, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Tuesday, August 15, 2023, to discuss the company’s financial results for the second quarter ended June 30, 2023, as well as the company’s corporate progress and other developments.

Key Points: 
  • ROSELAND, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Tuesday, August 15, 2023, to discuss the company’s financial results for the second quarter ended June 30, 2023, as well as the company’s corporate progress and other developments.
  • The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 612343.
  • A webcast and replay of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2306/48912 .
  • An audio replay of the call will be available through August 29, 2023 and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and by entering the access code: 48912.

INNOVATE Corp. Announces Second Quarter 2023 Results

Retrieved on: 
Wednesday, August 9, 2023
Linearity, Maintenance, Advertising, Society, FAST, Infrastructure, Transdermal, Paramount Global, Broadcasting, DBM, Trial of the century, Research, Continental, EBITDA, Azteca, R2, American Society for Artificial Internal Organs, Adjustment, FDA, Azteca América, Clinical study report, Spectrum, Management, Video game, Pharmaceutical industry, Tutoring, Ophthalmology, Gastroenterology

WEST PALM BEACH, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- INNOVATE Corp. (“INNOVATE” or the “Company”) (NYSE: VATE) announced today its consolidated results for the second quarter.

Key Points: 
  • “INNOVATE reported strong second quarter results with revenue of $368.8 million and adjusted EBITDA of $16.5 million, as our operating segments are capitalizing on attractive market opportunities," said Avie Glazer, Chairman of INNOVATE.
  • DBM Global Inc. ("DBMG") reported second quarter 2023 revenue of $362.4 million, a decrease of 5.2%, compared to $382.1 million in the prior year quarter.
  • For the second quarter of 2023, Broadcasting reported revenue of $5.7 million, compared to $9.1 million in the prior year quarter.
  • For the second quarter of 2023, Broadcasting reported Net Loss of $5.3 million compared to $5.7 million in the prior year quarter.

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 9, 2023
CDK, Clinical trial, Adenoid cystic carcinoma, Research, PLK1, Endometrial cancer, Patient, Cyclacel, Webcast, R, Ovarian cancer, CYCC, Research and development, Fine chemical, Pharmaceutical industry, Cryptocurrency, Broadcasting

BERKELEY HEIGHTS, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical leader in cell cycle checkpoint control developing innovative medicines based on cancer cell biology, announced today second quarter financial results and provided a business update.

Key Points: 
  • BERKELEY HEIGHTS, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical leader in cell cycle checkpoint control developing innovative medicines based on cancer cell biology, announced today second quarter financial results and provided a business update.
  • The operating plan includes discretionary expenditures, which if not incurred could extend liquidity requirements into the second quarter of 2024.
  • General and administrative expenses for the three months ended June 30, 2023 and 2022, remained relatively flat at $1.6 million.
  • Webcast link
    For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com .

Blue Bird Reports Fiscal Year 2023 Third Quarter Results; Turnaround Completed, Beats Guidance

Retrieved on: 
Wednesday, August 9, 2023
Preschool, Automotive Manufacturing, General Automotive, Manufacturing, Public Transport, Other Automotive, Transportation, Alternative Vehicles, Fuels, Other Education, Travel, Continuing, Fleet Management, University, Other Transport, Primary, Secondary, Trucking, Education, Automotive, EV, Electric Vehicles, Transport, Steel, Training, Bluebird, Telephone, Sale, EBITDA, Blue Bird Corporation, Webcast, CFO, Depreciation, Growth, Adjustment, Economics, Pharmaceutical industry, Video game, Security (finance), Broadcasting

Adjusted EBITDA was over 3X last year’s third quarter – in summary, a terrific quarter for Blue Bird, with an Adjusted EBITDA margin of almost 10%.

Key Points: 
  • Adjusted EBITDA was over 3X last year’s third quarter – in summary, a terrific quarter for Blue Bird, with an Adjusted EBITDA margin of almost 10%.
  • In the third quarter of fiscal 2023, 2,137 units were booked compared to 1,726 units booked for the same period in fiscal 2022.
  • Additionally, Parts sales increased $4.6 million, or 23.4%, for the third quarter of fiscal 2023 compared to the third quarter of fiscal 2022.
  • Blue Bird will discuss its third quarter 2023 results in a conference call at 4:30 PM ET today.

Quarterhill Announces Strong Q2 Fiscal 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023
Carbon, Interim, IRD, Telephone number (mathematics), William Morris, SG, International, WiLAN, Bank statement, Telephone, COVID-19, Tax, ETC, Wireless, Conversation, Research, Intelligent transportation system, Financial statement, Attention, History, USD, Sale, Invention, EBITDA, Retirement, Investment, Nature, Ix, ITS, SEDAR, Annual general meeting, TSX Venture Exchange, Management, Growth, Depreciation, TSX, PVT, Bookkeeping, Pension fund, Cryptocurrency, Rare-earth element, Pharmaceutical industry, Reinsurance, Broadcasting, Commercial property, Q2, Quarterhill, Adjustment, Accenture

Q2 2023 and year-to-date operating results from WiLAN, up to the date of sale on June 15, 2023, are reported as net (loss) income from discontinued operations.

Key Points: 
  • Q2 2023 and year-to-date operating results from WiLAN, up to the date of sale on June 15, 2023, are reported as net (loss) income from discontinued operations.
  • "IRD, our enforcement or commercial vehicle operations unit, had another strong quarter with the highest Q2 revenue in its history, while also generating strong Adjusted EBITDA margins.
  • As a percentage of revenue, SG&A in Q2 2023 was 16% compared to 33% in Q2 2022.
  • Quarterhill will host a conference call to discuss its financial results today at 10:00 AM Eastern Time.

Townsquare Announces Second Quarter Results That Demonstrate Ongoing Digital Advertising Strength

Retrieved on: 
Wednesday, August 9, 2023
Note, FCC, Contextual advertising, Marketing, Sale, Broadcast Advertising Clearance Centre, Townsquare Media, EBITDA, Investment, Radio, Digital marketing, Growth, The Company, Digital, Adjustment, NYSE, Clothing, Video game, Security (finance), Cryptocurrency, Life insurance, Arms industry, Broadcasting

PURCHASE, N.Y., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Townsquare Media, Inc. (NYSE: TSQ) (“Townsquare”, the "Company," "we," "us," or "our") announced today its financial results for the second quarter ended June 30, 2023.

Key Points: 
  • “I am pleased to share that Townsquare’s digital growth engine continued to drive results in the second quarter, demonstrating its strength and resiliency, as we delivered second quarter net revenue and Adjusted EBITDA that met our previously issued guidance.
  • With its differentiated and sophisticated products and solutions, our Digital Advertising segment was once again our largest driver of growth, increasing second quarter net revenue by +11% year-over-year.
  • We have three reportable operating segments, Subscription Digital Marketing Solutions, Digital Advertising and Broadcast Advertising.
  • The Digital Advertising segment, marketed externally as Townsquare Ignite, includes digital advertising on our owned and operated digital properties, our first party data digital management platform and our digital programmatic advertising platform.

Asetek - Q2 2023: Continued Liquid Cooling Market Improvement Drives Revenue Growth

Retrieved on: 
Wednesday, August 9, 2023
Kraken, NZXT, Partnership, Q&A, Conference call, Micro Center, ROG, EBITDA, CPU, Webcast, CEST, Nasdaq Copenhagen, Prodigy, Growth, OEM, Race, Invicta, Conference, ASUS, Video game, Cryptocurrency, Broadcasting, Asetek

The growth in both periods mainly reflects increased shipments of liquid cooling products.

Key Points: 
  • The growth in both periods mainly reflects increased shipments of liquid cooling products.
  • "We have seen continued improvement in the liquid cooling market with execution of product launch plans and high order activity driving revenue growth.
  • Combined with the extensive cost reductions implemented in 2022, this yielded a record Liquid cooling EBITDA in the second quarter.
  • On August 2, due to increased demand for liquid cooling products, the Company raised its revenue and operating profit expectations for 2023.

NeuroOne® to Report Third Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on August 14

Retrieved on: 
Tuesday, August 8, 2023
NMTC, DSM-IV codes, EDEN, Patient, Conference, Pharmaceutical industry, Broadcasting

EDEN PRAIRIE, Minn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its third quarter 2023 ended June 30, 2023 and provide a corporate update on August 14, 2023 at 4:30 PM Eastern Time.

Key Points: 
  • EDEN PRAIRIE, Minn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its third quarter 2023 ended June 30, 2023 and provide a corporate update on August 14, 2023 at 4:30 PM Eastern Time.
  • Conference Call and Webcast Information:

CSX Chief Financial Officer to Address Deutsche Bank Transportation Conference

Retrieved on: 
Tuesday, August 8, 2023
Webcast, CSX Corporation, Transport, Conference, Deutsche Bank, CSX, Cryptocurrency, Broadcasting, Film industry

JACKSONVILLE, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) --  CSX Corp. (NASDAQ: CSX) Executive Vice President and Chief Financial Officer, Sean Pelkey, will address the Deutsche Bank 2023 Transportation Conference in New York on Tuesday, August 15, at 9:00 am Eastern time.

Key Points: 
  • JACKSONVILLE, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) --  CSX Corp. (NASDAQ: CSX) Executive Vice President and Chief Financial Officer, Sean Pelkey, will address the Deutsche Bank 2023 Transportation Conference in New York on Tuesday, August 15, at 9:00 am Eastern time.
  • This address will be broadcast live via webcast at http://investors.csx.com.
  • A replay will be available following the conclusion of this event.
  • This announcement, as well as additional financial information, is available on the company’s website at http://investors.csx.com.

Nyxoah Reports Second Quarter and First Half 2023 Financial and Operating Results

Retrieved on: 
Tuesday, August 8, 2023
Acceleration, Webcast, Research, CET, Investment, Pharmaceutical industry, Video game, Broadcasting

Revenue was €1.1 million for the second quarter ending June 30, 2023, compared to €0.9 million for second quarter ending June 30, 2022.

Key Points: 
  • Revenue was €1.1 million for the second quarter ending June 30, 2023, compared to €0.9 million for second quarter ending June 30, 2022.
  • Selling, general and administrative expenses rose to €6.2 million for the second quarter of 2023, up from €4.5 million in the second quarter of 2022.
  • Total operating loss for the second quarter 2023 was €11.9 million versus €7.4 million in the second quarter of 2022.
  • Nyxoah’s financial report for the first half 2023, including details of the consolidated results, are available on the investor page of Nyxoah’s website ( https://investors.nyxoah.com/financials ).